Immunome's COVID-19 Antibody Neutralizes Two Variant Strains In Animal Studies

by Vandana Singh, Benzinga Editor

September 7, 2021 7:59 AM | 1 min read |

Immunome Inc's IMNM three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against SARS-CoV-2 Lambda (C.37) and Delta AY.1/2 (Delta Plus) variants in preclinical testing.
Related Content: Immunome's COVID-19 Antibody Shows Neutralizing Activity Against Delta Variant.
IMM-BCP-01 consists of three antibodies that bind to non-overlapping regions of the spike protein and show combinatorial activity against multiple strains of SARS-CoV-2.
The project was funded by the U.S. Department of Defense (DOD) in collaboration with the Defense Health Agency (DHA).
Price Action: IMNM shares are up 7.22% at $16.19 during the premarket session on the last check Tuesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.